Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06136546
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depressive Disorder, Major
- Inflammation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 25 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- May 7, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.